<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02409563</url>
  </required_header>
  <id_info>
    <org_study_id>2/2013</org_study_id>
    <secondary_id>ethics committee approval</secondary_id>
    <nct_id>NCT02409563</nct_id>
  </id_info>
  <brief_title>Nasal Budesonide Efficacy on Nasal FeNO in Children With Allergic Rhinitis</brief_title>
  <official_title>Effectiveness of Nasal Budesonide on Control of Airway Inflammation by Determining FeNO in Children With Allergic Rhinitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy</source>
  <brief_summary>
    <textblock>
      In clinical trials for treatment of allergic rhinitis a significant reduction of the total
      symptom score compared to baseline has been demonstrated by using nasal budesonide.Previous
      results in adults show that the assessment and monitoring del nasal fractional exhaled nitric
      oxide (nFeNO) is useful in controlling inflammation of nasal allergic rhinitis.

      Primary objective of this study is to evaluate efficacy of nasal budesonide (aqueous
      solution) on the nasal inflammation marker (nFeNO).

      Secondary outcomes are the evaluation of: changes in total nasal symptom score (Total Symptom
      Score, T5SS), changes in cell counts in nasal lavage (LN) and the changes reported sleep
      quality (Pittsburgh Sleep Quality Index, PSQI).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nasal nitric oxide (nFeNO)</measure>
    <time_frame>21 days</time_frame>
    <description>Assessment of the influence of nasal Budesonide (aqueous solution) on nasal FeNo (nFeNO) in children with allergic rhinitis.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Budesonide nasal (100 mcg bid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study will be randomized, controlled parallel group. After 1 week of phase baseline screening (Visit 1), patients will be randomized (1:4) with the assignment of a code (B-200_da 01 to 08, B-100_ 01 to 31) (day 0, Visit 2) in 2 groups: N1 (n = 8) = Budesonide nasal spray 100 mcg, 2 v / d; Patients return to control after the 1st week (day 7, Visit 3), after the 2nd week (day 14, Visit 4) and one week after the end of the treatment period (day 21, Visit 5). It will give a tolerance of ± 3 days for the timing of planned visits. In the phase of follow-up, (3 days after the last dose of drug) will be recorded the occurrence of adverse effects (Adverse Event, EA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide nasal (50 mcg bid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study will be randomized, controlled parallel group. After 1 week of phase baseline screening (Visit 1), patients will be randomized (1:4) with the assignment of a code (B-200_da 01 to 08, B-100_ 01 to 31) (day 0, Visit 2) in 2 groups: ; N2 (n = 31) = Budesonide nasal spray 50 mcg, 2 v / d. Patients return to control after the 1st week (day 7, Visit 3), after the 2nd week (day 14, Visit 4) and one week after the end of the treatment period (day 21, Visit 5). It will give a tolerance of ± 3 days for the timing of planned visits. In the phase of follow-up, (3 days after the last dose of drug) will be recorded the occurrence of adverse effects (Adverse Event, EA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide nasal spray (100 mcg bid)</intervention_name>
    <arm_group_label>Budesonide nasal (100 mcg bid)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide nasal spray (50 mcg bid</intervention_name>
    <arm_group_label>Budesonide nasal (50 mcg bid)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  history of allergic rhinitis for at least 1 year

          -  children aged 6 - 14 years

          -  Total Symptom Score (T5SS) more than 6 in the last 4 days before the screening visit

        Exclusion Criteria:

          -  signs of acute respiratory infection

          -  systemic immunological and metabolic disease

          -  major malformations of the upper airways

          -  topical or systemic therapy with antibiotics, antihistamines and corticosteroids in
             the 30 days prior to the study

          -  patient active smoker
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council</name>
      <address>
        <city>Palermo</city>
        <state>Sicily</state>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.ibim.cnr.it</url>
    <description>Click here for more information about this study: thematic area, pediatrics</description>
  </link>
  <results_reference>
    <citation>Meltzer EO. Clinical and antiinflammatory effects of intranasal budesonide aqueous pump spray in the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol. 1998 Aug;81(2):128-34.</citation>
    <PMID>9723557</PMID>
  </results_reference>
  <results_reference>
    <citation>Pedroletti C, Lundahl J, Alving K, Hedlin G. Effect of nasal steroid treatment on airway inflammation determined by exhaled nitric oxide in allergic schoolchildren with perennial rhinitis and asthma. Pediatr Allergy Immunol. 2008 May;19(3):219-26. doi: 10.1111/j.1399-3038.2007.00613.x.</citation>
    <PMID>18399898</PMID>
  </results_reference>
  <results_reference>
    <citation>Meltzer EO, Munafo DA, Chung W, Gopalan G, Varghese ST. Intranasal mometasone furoate therapy for allergic rhinitis symptoms and rhinitis-disturbed sleep. Ann Allergy Asthma Immunol. 2010 Jul;105(1):65-74. doi: 10.1016/j.anai.2010.04.020.</citation>
    <PMID>20642206</PMID>
  </results_reference>
  <results_reference>
    <citation>Bellodi S, Tosca MA, Pulvirenti G, Petecchia L, Serpero L, Silvestri M, Sabatini F, Battistini E, Rossi GA. Activity of budesonide on nasal neutrophilic inflammation and obstruction in children with recurrent upper airway infections. A preliminary investigation. Int J Pediatr Otorhinolaryngol. 2006 Mar;70(3):445-52. Epub 2005 Sep 2.</citation>
    <PMID>16140398</PMID>
  </results_reference>
  <results_reference>
    <citation>Baraldi E, Azzolin NM, Carrà S, Dario C, Marchesini L, Zacchello F. Effect of topical steroids on nasal nitric oxide production in children with perennial allergic rhinitis: a pilot study. Respir Med. 1998 Mar;92(3):558-61.</citation>
    <PMID>9692122</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2013</study_first_submitted>
  <study_first_submitted_qc>April 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2015</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy</investigator_affiliation>
    <investigator_full_name>Stefania La Grutta, MD</investigator_full_name>
    <investigator_title>Senior Researcher</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

